Regeneron Pharmaceuticals, Inc. Common Stock Earnings Dividend

Regeneron Pharmaceuticals, Inc. Common Stock’s revenue jumped 16.73% since last year same period to $4290.7Mn in the Q2 2026. On a quarterly growth basis, Regeneron Pharmaceuticals, Inc. Common Stock has generated 19.01% jump in its revenue since last 3-months.

Regeneron Pharmaceuticals, Inc. Common Stock’s net profit fell -6.81% since last year same period to $1296.9Mn in the Q2 2026. On a quarterly growth basis, Regeneron Pharmaceuticals, Inc. Common Stock has generated 78.34% jump in its net profits since last 3-months.

Regeneron Pharmaceuticals, Inc. Common Stock’s net profit margin fell -20.17% since last year same period to 30.23% in the Q2 2026. On a quarterly growth basis, Regeneron Pharmaceuticals, Inc. Common Stock has generated 49.86% jump in its net profit margins since last 3-months.

Regeneron Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at 8 - a -10.11% fall from last quarter’s estimates.

Regeneron Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at 8.

Regeneron Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) fell -2.79% since last year same period to 12.53 in the Q2 2026. This indicates that the Regeneron Pharmaceuticals, Inc. Common Stock has generated -2.79% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Regeneron Pharmaceuticals, Inc. Common Stock declared 0.94 dividend per share during the earnings announcement for Q2 2026.